EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Artificial intelligence in drug development

Kang Zhang iD, Xin Yang, Yifei Wang iD, Yunfang Yu, Niu Huang iD, Gen Li, Xiaokun Li, Joseph C Wu, Shengyong Yang iD

Nature Medicine · 2025-01 · 31 (1) · 45-59

DOI: 10.1038/s41591-024-03434-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nature Medicine, online erschienen am 20.01.2025. Verfasst von Kang Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Eye Hospital and Institute for Advanced Study on Eye Health and Diseases, Institute for clinical Data Science, Wenzhou Medical University, Wenzhou, C…. Hauptthemen laut MEDLINE: Artificial Intelligence, Drug Development. Die Arbeit wurde bisher 552-mal zitiert (Crossref) und nennt 248 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug development is a complex and time-consuming endeavor that traditionally relies on the experience of drug developers and trial-and-error experimentation. The advent of artificial intelligence (AI) technologies, particularly emerging large language models and generative AI, is poised to redefine this paradigm. The integration of AI-driven methodologies into the drug development pipeline has already heralded subtle yet meaningful enhancements in both the efficiency and effectiveness of this process. Here we present an overview of recent advancements in AI applications across the entire drug development workflow, encompassing the identification of disease targets, drug discovery, preclinical and clinical studies, and post-market surveillance. Lastly, we critically examine the prevailing challenges to highlight promising future research directions in AI-augmented drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceDrug DevelopmentHumansDrug Discovery

Autor:innen und Institutionen

  • Eye Hospital and Institute for Advanced Study on Eye Health and Diseases, Institute for clinical Data Science, Wenzhou Medical University, Wenzhou, China. kang.zhang@gmail.com.
  • State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Wenzhou Medical University, Wenzhou, China. kang.zhang@gmail.com.
  • Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Institute for AI in Medicine and faculty of Medicine, Macau University of Science and Technology, Macau, China.
  • Guangzhou National Laboratory, Guangzhou, China.

ORCID-Profile: Kang Zhang, Yifei Wang, Niu Huang, Shengyong Yang

Zitieren

APA

Zhang, K., Yang, X., Wang, Y., Yu, Y., Huang, N., Li, G., Li, X., Wu, J. C., & Yang, S. (2025). Artificial intelligence in drug development. Nature Medicine, 31(1), 45-59. https://doi.org/10.1038/s41591-024-03434-4

Vancouver

Zhang K, Yang X, Wang Y, Yu Y, Huang N, Li G, et al. Artificial intelligence in drug development. Nature Medicine. 2025;31(1):45-59. doi:10.1038/s41591-024-03434-4

BibTeX
@article{Zhang2025,
  author = {Zhang, Kang and Yang, Xin and Wang, Yifei and Yu, Yunfang and Huang, Niu and Li, Gen and Li, Xiaokun and Wu, Joseph C and Yang, Shengyong},
  title = {Artificial intelligence in drug development},
  journal = {Nature Medicine},
  year = {2025},
  volume = {31},
  number = {1},
  pages = {45--59},
  doi = {10.1038/s41591-024-03434-4}
}
Kostenlos starten →